Davalintide

Drug Profile

Davalintide

Alternative Names: AC 2307; Second generation amylinomimetic

Latest Information Update: 28 Dec 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amylin Pharmaceuticals
  • Class Multiprotein complexes; Obesity therapies; Peptides; Proteins
  • Mechanism of Action Amylin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Obesity; Psychiatric disorders

Most Recent Events

  • 25 Dec 2012 Amylin Pharmaceuticals and Takeda terminate their agreement for this programme
  • 24 Feb 2010 Discontinued - Phase-II for Obesity in USA (SC)
  • 24 Feb 2010 Discontinued - Preclinical for Psychiatric disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top